Although KIT and PDGFRA genotyping provide important biomarker data for the clinical management of GIST [20], neither here were found to be strongly linked with prognosis in this current study possibly due to the low number of studies reporting these data. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.